SABS Stock Summary and Trading Ideas (Sab Biotherapeutics | NASDAQ:SABS)

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Sab Biotherapeutics trades on the NASDAQ stock market under the symbol SABS.

As of November 13, 2026, SABS stock price declined to $2.96 with 622,690 million shares trading.

SABS has a beta of 0.85, meaning it tends to be less sensitive to market movements. SABS has a correlation of 0.03 to the broad based SPY ETF.

SABS has a market cap of $266.66 million. This is considered a Small Cap stock.

In the last 3 years, SABS traded as high as $9.72 and as low as $1.00.

The top ETF exchange traded funds that SABS belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

SABS has underperformed the market in the last year with a price return of -13.2% while the SPY ETF gained +11.5%. SABS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -22.1% and -8.4%, respectively, while the SPY returned -2.1% and -1.9%, respectively.

SABS support price is $2.91 and resistance is $3.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SABS shares will trade within this expected range on the day.